Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer
December 13, 2022 02:00 ET
|
Glycotope
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer San...
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform
March 24, 2022 03:00 ET
|
Glycotope
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform Expansion of senior team to focus on drug discovery and developmentPlatform combines glycobiology...
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting
November 15, 2021 03:00 ET
|
Glycotope
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope Poster Presentation at the 2021 Society...